Chronic Adverse Drug Reactions of Phenytoin: A Comprehensive Review
DOI:
https://doi.org/10.22270/ajprd.v13i3.1572Abstract
Phenytoin remains a cornerstone in the management of epilepsy and certain seizure disorders. However, its use is frequently complicated by a wide array of adverse drug reactions (ADRs) affecting multiple organ systems. This review aims to provide an in-depth overview of the chronic toxicities linked to phenytoin, discuss the underlying mechanisms, propose clinical management strategies, and highlight potential safer alternatives for long-term epilepsy management.
Downloads
References
Belete TB. Mechanism of action of phenytoin in neuropharmacology. [Journal Name]. 2023;[Volume(Issue)]:pages.
Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2(8):473-481.
Perucca E. Pharmacoresistance in epilepsy: how should it be defined? CNS Drugs. 1998;10(3):171-179.
Brodie MJ, Kwan P. Current position of phenobarbital in epilepsy and its future. Epilepsia. 2012;53 Suppl 8:40-46.
Löscher W, Potschka H. Role of drug efflux transporters in the brain for drug resistance in epilepsy. Handb Exp Pharmacol. 2011;(201):445-473.
Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med. 2004;10(7):685-692.
McNamara JO. Pharmacotherapy of the epilepsies. In: Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill; 2018. p. 275-301.
Hageman NS, Okun MS. Phenytoin-induced cerebellar degeneration. Neurology. 2001;56(5):686-688.
Perucca E. Adverse effects of antiepileptic drugs. Lancet Neurol. 2005;4(11):693-702.
Miller DR, Cohen PR. Phenytoin-induced cutaneous adverse drug reactions. South Med J. 1993;86(10):1148-1152.
Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331(19):1272-1285.
Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug Information Handbook. 24th ed. Hudson (OH): Lexicomp; 2016.
Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ. ACG Clinical Guideline: The diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950-966.
Petty SJ, O'Brien TJ, Wark JD. Anti-epileptic medication and bone health. Osteoporos Int. 2007;18(2):129-142.
Pack AM. The association between antiepileptic drugs and bone disease. Epilepsy Curr. 2003;3(3):91-95.
Patsalos PN. Therapeutic drug monitoring of antiepileptic drugs by use of saliva. Ther Drug Monit. 1999;21(6):674-679.
Brodie MJ. Antiepileptic drug therapy the story so far. Seizure. 2010;19(10):650-655.
Bøttiger LE, Westerholm B. Megaloblastic anemia induced by anticonvulsant drugs. Epilepsia. 1970;11(4):377-383.
Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet. 2006;45(4):351-363.
Pack AM, Morrell MJ. Epilepsy and bone health in adults. Epilepsy Behav. 2004;5 Suppl 2:S24-S29.
Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239-1276.
Shorvon S. The clinical efficacy of newer antiepileptic drugs. Epilepsia. 2004;45 Suppl 6:46-50.
Sander JW. The use of antiepileptic drugs—principles and practice. Epilepsia. 2004;45 Suppl 6:28-34.
Stephen LJ, Brodie MJ. Seizure freedom with more than one antiepileptic drug. Seizure. 2002;11(6):349-351.
Bhagavati S. Phenytoin toxicity: An overview. J Clin Neurosci. 2019;62:1-5. doi: 10.1016/j.jocn.2019.01.007.
Brodie MJ. Phenytoin: 80 years young, but with an uncertain future. Epilepsy Res. 2017;137:1-4. doi: 10.1016/j.eplepsyres.2017.08.007.
Herman ST, Walther E. Adverse effects of antiepileptic drugs: A brief overview. CNS Drugs. 2018;32(4):383-92. doi: 10.1007/s40263-018-0523-9.
McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperavičiūtė D, Carrington M, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364(12):1134-43. doi: 10.1056/NEJMoa1013297.
Pack AM. Epilepsy and bone health: The role of antiepileptic drugs. Curr Neurol Neurosci Rep. 2018;18(7):44. doi: 10.1007/s11910-018-0853-3.
Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49(7):1239-76. doi: 10.1111/j.1528-1167.2008.01561.x.
Published
How to Cite
Issue
Section
Copyright (c) 2025 Jamdade Sonali Lala, Ayodhya Tanaji Pardhe, Dr. V. N. Deshmukha, Dr. Rajesh Mandade
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.